The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Results from a Phase I/II study of golcadomide in R/R follicular lymphoma
Julio Chavez, MD, MS, Moffitt Cancer Center, Tampa, FL, outlines the results from a Phase I/II study (NCT03930953) of golcadomide, a cereblon E3 ligase modulator (CELMoD), in 31 patients with relapsed/refractory (R/R) follicular lymphoma (FL). Despite the study being conducted in a high-risk patient population, an overall response rate (ORR) of 70% and a complete response (CR) rate of 40% were observed. The agent was well tolerated, and any cases of cytopenia and neutropenia were managed with supportive care, such as growth factors. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting: Genmab, Kite, Novartis, BMS, Allogene.
